Ad
Monday, 19 June 2017
Novartis wins European approval for biosimilar version of Roche's MabThera
ZURICH (Reuters) - Swiss drugmaker Novartis on Monday said it had won European approval for its biosimilar version of Roche's blockbuster Rituxan as the crosstown rivals go head-to-head on a drug to treat blood cancers and immunological diseases.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment